76 related articles for article (PubMed ID: 16104083)
1. [Our experiences in the treatment of myelodysplastic syndromes].
Belić A; Pejin D; Stefanović N; Spasojević J; Popović S; Uzurov V; Kljajić D
Med Pregl; 1992; 45(3-4):106-10. PubMed ID: 16104083
[TBL] [Abstract][Full Text] [Related]
2. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
4. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
[TBL] [Abstract][Full Text] [Related]
6. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
7. A study of the haematologic spectrum of myelodysplastic syndrome.
Kini J; Khadilkar UN; Dayal JP
Indian J Pathol Microbiol; 2001 Jan; 44(1):9-12. PubMed ID: 12561987
[TBL] [Abstract][Full Text] [Related]
8. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
10. [Clinical investigation of interferons in the preleukemic state (CML and MDS)].
Koyama S
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1191-7. PubMed ID: 3132893
[TBL] [Abstract][Full Text] [Related]
11. [Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes].
Jaeger M; Aul C; Söhngen D; Germing U; Schneider W
Beitr Infusionsther; 1992; 30():464-8. PubMed ID: 1284762
[TBL] [Abstract][Full Text] [Related]
12. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
Chen SC; Jiang B; Da WM; Gong M; Guan M
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
[TBL] [Abstract][Full Text] [Related]
13. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
16. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
18. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
[TBL] [Abstract][Full Text] [Related]
19. [Vitamin K2 therapy for myelodysplastic syndrome].
Abe Y; Muta K; Hirase N; Choi I; Matsushima T; Hara K; Taguchi F; Suematsu E; Shibata K; Uike N; Nishimura J; Nawata H
Rinsho Ketsueki; 2002 Feb; 43(2):117-21. PubMed ID: 11925874
[TBL] [Abstract][Full Text] [Related]
20. [How to improve the results of treatment of myelodysplastic syndromes in the studies of Polish pediatric leukemia/lymphoma group].
Chybicka A; Kołecki P; Pietras W; Wójcik D; Turkiewicz D; Armata J; Eliasińska A; Kowalczyk J; Jackowska T; Klus K; Matysiak M; Krauze A; Stefańska K; Rokicka-Milewska R; Wiśniewska-Slusarz H
Wiad Lek; 1998; 51 Suppl 4():45-51. PubMed ID: 10731943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
